Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1963 1
1964 2
1965 2
1966 3
1967 3
1969 2
1970 3
1972 1
1974 2
1976 1
1977 3
1978 2
1980 4
1981 3
1982 7
1983 3
1984 6
1985 6
1986 9
1987 5
1988 4
1989 8
1990 8
1991 19
1992 8
1993 15
1994 5
1995 19
1996 15
1997 12
1998 13
1999 12
2000 12
2001 14
2002 16
2003 28
2004 17
2005 22
2006 23
2007 21
2008 26
2009 27
2010 29
2011 28
2012 27
2013 41
2014 49
2015 44
2016 36
2017 54
2018 44
2019 46
2020 55
2021 59
2022 48
2023 16
Text availability
Article attribute
Article type
Publication date

Search Results

894 results
Results by year
Filters applied: . Clear all
Page 1
A Neural Circuit for Gut-Induced Reward.
Han W, Tellez LA, Perkins MH, Perez IO, Qu T, Ferreira J, Ferreira TL, Quinn D, Liu ZW, Gao XB, Kaelberer MM, Bohórquez DV, Shammah-Lagnado SJ, de Lartigue G, de Araujo IE. Han W, et al. Among authors: quinn d. Cell. 2018 Oct 18;175(3):665-678.e23. doi: 10.1016/j.cell.2018.08.049. Epub 2018 Sep 20. Cell. 2018. PMID: 30245012 Free PMC article.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. Among authors: quinn di. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. Hyman DM, et al. Among authors: quinn di. Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Nature. 2018. PMID: 29420467 Free PMC article. Clinical Trial.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Balar AV, et al. Among authors: quinn di. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Lancet. 2017. PMID: 27939400 Free PMC article. Clinical Trial.
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF. Fradet Y, et al. Among authors: quinn di. Ann Oncol. 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127. Ann Oncol. 2019. PMID: 31050707 Free PMC article. Clinical Trial.
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP. Rosenberg J, et al. Among authors: quinn di. J Clin Oncol. 2020 Apr 1;38(10):1041-1049. doi: 10.1200/JCO.19.02044. Epub 2020 Feb 7. J Clin Oncol. 2020. PMID: 32031899 Free PMC article. Clinical Trial.
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, Choueiri TK, Culine S, Gerritsen W, Gurney H, Quinn DI, Vuky J, Vogelzang NJ, Cristescu R, Lunceford J, Saadatpour A, Loboda A, Ma J, Rajasagi M, Godwin JL, Homet Moreno B, Grivas P. Bellmunt J, et al. Among authors: quinn di. Clin Cancer Res. 2022 May 13;28(10):2050-2060. doi: 10.1158/1078-0432.CCR-21-3089. Clin Cancer Res. 2022. PMID: 35247908 Clinical Trial.
Concussion.
Master CL, Mayer AR, Quinn D, Grady MF. Master CL, et al. Among authors: quinn d. Ann Intern Med. 2018 Jul 3;169(1):ITC1-ITC16. doi: 10.7326/AITC201807030. Ann Intern Med. 2018. PMID: 29971425 Review.
894 results